These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

81 related items for PubMed ID: 2834499

  • 1. [Low molecular weight heparin (CY 222) levels during hemodialysis sessions. Comparison of various chromogenic and chronometric methods. Problem of standardization].
    Roussel B, Dieval J, Bayrou B, Delobel J.
    J Mal Vasc; 1987; 12 Suppl B():85-9. PubMed ID: 2834499
    [Abstract] [Full Text] [Related]

  • 2. [Anticoagulation in hemodialysis sessions with a low molecular weight heparin (CY 222, Choay). Dosage studies in chronic hemodialysis. Its use in patients at high risk of hemorrhage].
    Dieval J, Morinière P, Roussel B, Bayrou B, Fournier A, Delobel J.
    J Mal Vasc; 1987; 12 Suppl B():114-8. PubMed ID: 2834482
    [Abstract] [Full Text] [Related]

  • 3. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
    Harenberg J.
    J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
    [Abstract] [Full Text] [Related]

  • 4. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J, Haaf B, Dempfle CE, Stehle G, Heene DL.
    Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456
    [Abstract] [Full Text] [Related]

  • 5. A new chronometric assay to determine plasma antifactor Xa activity which is insensitive to the antithrombin activity of low molecular weight heparins.
    Dignac M, Gabaig AM, Cambus JP, Boneu B.
    Nouv Rev Fr Hematol (1978); 1994; 35(6):545-9. PubMed ID: 8152901
    [Abstract] [Full Text] [Related]

  • 6. [Biological monitoring of low molecular weight heparin. Value of a new chronometric tests, the Heptest].
    Delahousse B, Gruel Y, Moalic P, Foloppe P, Leroy J.
    J Mal Vasc; 1987; 12 Suppl B():71-3. PubMed ID: 2834496
    [No Abstract] [Full Text] [Related]

  • 7. [Automatization of heparin determination using chronometric evaluation of anti-Xa activity of the AT III-heparin complex].
    Sampol J, Rossi JM, Lejay G.
    Ann Biol Clin (Paris); 1984; 42(1):21-3. PubMed ID: 6731952
    [Abstract] [Full Text] [Related]

  • 8. [Chronopharmacology of fractionated heparin (nadroparin) administrated by subcutaneous route at prophylactic doses in healthy volunteers].
    Mismetti P, Perpoint B, Laporte-Simitsidis S, Tardy-Poncet B, Reynaud J, Cherrah Y, Ollagnier M, Queneau P, Decousus H.
    Therapie; 1992 Nov; 47(6):557-60. PubMed ID: 1338741
    [Abstract] [Full Text] [Related]

  • 9. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R, Grebe S.
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [Abstract] [Full Text] [Related]

  • 10. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G, Heiden M, Köhler M.
    Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
    [Abstract] [Full Text] [Related]

  • 11. Effects of standard heparin and a low molecular weight heparin (Kabi 2165) on fibrinolysis.
    Agnelli G, Borm J, Cosmi B, Levi M, ten Cate JW.
    Thromb Haemost; 1988 Oct 31; 60(2):311-3. PubMed ID: 2851195
    [Abstract] [Full Text] [Related]

  • 12. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma.
    Ofosu FA, Lormeau JC, Craven S, Dewar L, Anvari N.
    Thromb Haemost; 1994 Dec 31; 72(6):862-8. PubMed ID: 7740455
    [Abstract] [Full Text] [Related]

  • 13. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin).
    Persson E.
    Acta Med Scand Suppl; 1988 Dec 31; 724():1-56. PubMed ID: 2843005
    [Abstract] [Full Text] [Related]

  • 14. Clinical pharmacology of a new low molecular weight heparin (Alfa LMWH-Fluxum).
    Dettori AG, Tagliaferri A, Dall'Aglio E, Pini M.
    Int Angiol; 1988 Dec 31; 7(3 Suppl):7-18. PubMed ID: 2850327
    [Abstract] [Full Text] [Related]

  • 15. [Low molecular weight heparin fractions. Comparative preclinical study of various parameters].
    Fareed J.
    J Mal Vasc; 1987 Dec 31; 12 Suppl B():59-63. PubMed ID: 2834492
    [Abstract] [Full Text] [Related]

  • 16. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
    Frank RD, Brandenburg VM, Lanzmich R, Floege J.
    Nephrol Dial Transplant; 2004 Jun 31; 19(6):1552-8. PubMed ID: 15034159
    [Abstract] [Full Text] [Related]

  • 17. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability.
    Kitchen S, Iampietro R, Woolley AM, Preston FE.
    Thromb Haemost; 1999 Oct 31; 82(4):1289-93. PubMed ID: 10544915
    [Abstract] [Full Text] [Related]

  • 18. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis.
    Bratt G, Törnebohm E, Granqvist S, Aberg W, Lockner D.
    Thromb Haemost; 1985 Dec 17; 54(4):813-7. PubMed ID: 3911482
    [Abstract] [Full Text] [Related]

  • 19. [Biological monitoring of treatment with low molecular weight heparin].
    Aiach M.
    J Mal Vasc; 1987 Dec 17; 12 Suppl B():66-7. PubMed ID: 2834494
    [Abstract] [Full Text] [Related]

  • 20. [Biological modifications induced by 3 low molecular weight heparins, PK 10169, Kabi 2165 and CY 216, compared to unfractionated heparin injected subcutaneously in healthy subjects in general surgery and in aged subjects in internal medicine].
    Bara L, Combe-Tamzali S, Conard J, Horellou MH, Samama M.
    J Mal Vasc; 1987 Dec 17; 12 Suppl B():78-84. PubMed ID: 2834498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.